Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall survival (OS). Sorafenib plus doxorubicin combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: El Dika, Imane, Capanu, Marinela, Chou, Joanne F., Harding, James J., Ly, Michele, Hrabovsky, Anna D., Do, Richard K.G., Shia, Jinru, Millang, Brittanie, Ma, Jennifer, O’Reilly, Eileen M., Abou‐Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571806/
https://www.ncbi.nlm.nih.gov/pubmed/32841541
http://dx.doi.org/10.1002/cam4.3389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571806/
https://www.ncbi.nlm.nih.gov/pubmed/32841541
http://dx.doi.org/10.1002/cam4.3389

Ejemplares similares